Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study

By sjmartinez • August 20, 2024

Curtis JL, Bateman LA, Murray S, Couper DJ, Labaki WW, Freeman CM, Arnold KB, Christenson SA, Alexis NE, Kesimer M, Boucher RC, Kaner RJ, Barjaktarevic I, Cooper CB, Hoffman EA, Barr RG, Bleecker ER, Bowler RP, Comellas A, Dransfield MT, Freedman MB, Hansel NN, Krishnan JA, Marchetti N, Meyers DA, Ohar J, O'Neal WK, Ortega VE, Paine Iii R, Peters SP, Smith BM, Wedzicha JA, Wells JM, Woodruff PG, Han MK, Martinez FJ. Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study. Chronic Obstr Pulm Dis. 2024 Aug 16. doi: 10.15326/jcopdf.2023.0490. Epub ahead of print. PMID: 39159077.

When Is Enough Enough? Additional Evidence of the Power of Zero

Budoff MJ. When Is Enough Enough? Additional Evidence of the Power of Zero. Circ Cardiovasc Imaging. 2024 Dec 20:e017714. doi: 10.1161/CIRCIMAGING.124.017714. Epub ahead of print.[...]

Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021

Danpanichkul P, Duangsonk K, Tham EKJ, Tothanarungroj P, Auttapracha T, Prasitsumrit V, Sim B, Tung D, Barba R, Wong RJ, Leggio L, Yang JD, Chen[...]

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]